AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,970,000 | -12.6% | 120,000 | 0.0% | 0.05% | -23.3% |
Q2 2023 | $3,398,400 | +29.7% | 120,000 | +5.2% | 0.06% | +17.6% |
Q1 2023 | $2,620,555 | +55.5% | 114,086 | +90.1% | 0.05% | +96.2% |
Q4 2022 | $1,684,800 | -58.9% | 60,000 | -58.6% | 0.03% | -54.4% |
Q3 2022 | $4,100,000 | -8.6% | 145,000 | -5.8% | 0.06% | +5.6% |
Q1 2022 | $4,484,000 | +4.1% | 154,000 | +17.6% | 0.05% | +12.5% |
Q4 2021 | $4,308,000 | -34.3% | 131,000 | +10.1% | 0.05% | -44.2% |
Q2 2021 | $6,560,000 | +62.9% | 119,000 | +52.6% | 0.09% | -1.1% |
Q1 2021 | $4,028,000 | -4.2% | 78,000 | -19.6% | 0.09% | -9.4% |
Q4 2020 | $4,204,000 | +13.2% | 97,000 | -8.5% | 0.10% | +11.6% |
Q3 2020 | $3,713,000 | -34.5% | 106,000 | 0.0% | 0.09% | -54.5% |
Q2 2020 | $5,671,000 | +188.2% | 106,000 | +91.0% | 0.19% | +70.3% |
Q1 2020 | $1,968,000 | -43.9% | 55,500 | -24.5% | 0.11% | -5.9% |
Q4 2019 | $3,508,000 | -68.7% | 73,500 | -78.7% | 0.12% | -79.8% |
Q3 2019 | $11,194,000 | – | 345,600 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |